Amyris Enters Second Major Product Development & Production Agreement With Royal DSM
Amyris, Inc. recently announced it has entered into a product development and production agreement for Vitamin A with Koninklijke DSM N.V. (Royal DSM). This marks the second such agreement between the two parties.
DSM is partnering with Amyris to fund the development of the technology to produce Vitamin A on a cost-advantaged basis utilizing Amyris’s and DSM’s capabilities. Once scaled, DSM will take the product to market utilizing its global channel and market access for animal and human nutrition and health. Amyris will develop, scale and produce a key ingredient for Vitamin A to supply exclusively to DSM.
“We are pleased to announce our second major product development and production agreement with DSM that we expect will end up being one of several going forward. This agreement is consistent with our collaboration business model and includes payment for development and value share on product production and delivery,” said John Melo, Amyris President & CEO. “Our partnership with DSM is a key example of our disruptive business model that leverages Amyris technology to achieve cost-advantaged product innovation with a successful global partner that can rapidly scale sales. The results are expected to drive robust product sales growth for Amyris while continuing to support our partner’s competitive position.”
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise™ products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. For more information, visit www.amyris.com.
Total Page Views: 1401
